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Abstract
Human testis development starts from around 42 days post conception with a transient wave of SRY expression followed by up-
regulation of testis specific genes and a distinct set of morphological, paracrine and endocrine events. Although anatomical
changes in the ovary are less marked, a distinct sub-set of ovary specific genes are also expressed during this time. The furin-
domain containing peptide R-spondin1 (RSPO1) has recently emerged as an important regulator of ovary development through
up-regulation of the WNT/b-catenin pathway to oppose testis formation. Here, we show that RSPO1 is upregulated in the ovary
but not in the testis during critical early stages of gonad development in humans (between 6–9 weeks post conception),
whereas the expression of the related genesWNT4 and CTNNB1 (encoding b catenin) is not significantly different between these
tissues. Furthermore, reduced R-spondin1 function in the ovotestis of an individual (46,XX) with a RSPO1 mutation leads to
reduced b-catenin protein andWNT4mRNA levels, consistent with down regulation of ovarian pathways. Transfection of wild-
type RSPO1 cDNA resulted in weak dose-dependent activation of a b-catenin responsive TOPFLASH reporter (1.8 fold
maximum), whereas co-transfection of CTNNB1 (encoding b-catenin) with RSPO1 resulted in dose-dependent synergistic
augmentation of this reporter (approximately 10 fold). Furthermore, R-spondin1 showed strong nuclear localization in several
different cell lines. Taken together, these data show that R-spondin1 is upregulated during critical stages of early human ovary
development and may function as a tissue-specific amplifier of b-catenin signaling to oppose testis determination.
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Introduction
Sex development is a complex process that requires the integrated
interaction of a network of different endocrine and paracrine
signaling pathways, transcription factors and steroid hormones,
during a critical time period in embryogenesis. In humans, this
process starts from around 6 weeks post-conception with the
expression of SRY in the developing testis and several other critical
genes downstream of SRY have now been discovered from human
and mouse studies [1–3].
For many years, testis development was believed to be the more
active process. Although the morphological changes in the
developing testis and in surrounding structures are more marked
than in the developing ovary [4], recent gene expression data from
mice have shown that a significant subset of ovary-specific genes are
also expressed during this critical stage of embryogenesis [5,6].
Whilst some of these genes may represent ovary-determining or
maintenance genes, data from mice and humans suggest that
certain key components of the Wnt signaling pathway, and other
potential nuclear targets (e.g. NR0B1) may antagonize or oppose
testis development [7–12]. These effects may be mediated by b-
catenin signaling, which has recently been shown to be necessary in
the ovary for preventing testis-like characteristics, but to be
dispensable in the embryonic testis [13]. Furthermore, Foxl2 seems
necessary to maintain the ovary in a differentiated state [14]. Thus,
ovary development is likely to be a more active process than
originally thought, and disruption of genes in this cascade may lead
to complete or partial transdifferentiation of ovarian tissue into testis
(e.g. testicular DSD (Disorder of Sex Development) [‘‘XX males’’],
ovotesticular DSD [‘‘46,XX true hermaphrodites’’], respectively).
One of the most significant advances in understanding ovary
development came through the discovery of single-gene defects in
RSPO1 (encoding R-spondin1) in several patients with testicular
DSD (‘‘SRY negative XX males’’), palmoplantar hyperkeratosis
and a predisposition to skin tumors (OMIM *609595) [15]. R-
spondin1 belongs to a family of secreted furin-like domain
containing proteins that are believed to interact with canonical
Wnt signaling pathways by influencing externalization of the
LRP6 cell membrane receptor, as well as through stabilization of
intracellular b-catenin [16–18]. R-spondin1 has been shown to be
expressed in the mouse ovary at a critical time in development as
well as in the developing dermis, kidney and dermal papilla of
adult skin [15]. Targeted deletion of Rspo1 in mice results in testis
development in chromosomal XX females [19,20]. The report of a
homozygous splice mutation in RSPO1 predicted to result in an in-
frame deletion of the first furin-like domain in R-spondin1
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(p.Ile32_Ile95del) in a patient with 46,XX ovotesticular DSD
(formerly ‘‘true hermaphroditism’’) has provided further evidence
for the critical role of this protein in humans [21].
Despite these advances, relatively little is known about the
expression of R-spondin1 in early human ovary development or its
downstream interactions with components of the Wnt signaling
pathway. Here, we show upregulation of R-spondin1 in the
human ovary at a critical time in development, augmentation of b-
catenin signaling by RSPO1 in a human cell system, and nuclear
localization of R-spondin1.
Results
RSPO1 expression increases at key stages of early human
ovary development
Analysis of CTNNB1 (ENSG00000168036), WNT4 (ENSG-
00000162552), and RSPO1 (ENSG00000169218) in human fetal
gonads between 6–9 weeks post-conception showed significantly
higher expression of RSPO1 in the developing ovary compared to
testis, whereas no significant differences in the expression of CTNNB1
or WNT4 were seen (Fig. 1A). Analysis of RSPO1 expression levels
across this time course revealed an incremental rise in mRNA levels
in the ovary from 6-7w to 8w (Fig. 1B). In contrast, RSPO1 mRNA
levels were lower in the developing testis and did not change
throughout these key developmental stages (Fig. 1B).
b-catenin and WNT4 expression in RSPO1 altered
ovotestis
Mutant (MT) R-spondin1 lacks the first furin-like domain and
has been reported to be responsible for abnormal ovary
development in a patient with 46,XX ovotesticular DSD [21].
The effects of wild-type (WT) and mutant (MT) R-spondin1 on the
expression of the CTNNB1 gene and its encoded protein, b-
catenin, were studied in vivo using RNA and protein obtained from
the patient’s ovotestis (OT) and from normal ovary (Ov) control.
RT-PCR analysis showed no noticeable difference in b-catenin
Figure 1. RSPO1 expression increases at key stages of early human ovary development. (A) Analysis of CTNNB1, WNT4, and RSPO1 in
human fetal gonads between 6–9 weeks post-conception. Testis and ovary samples showed higher expression of CTNNB1 (ANOVA, p,0.001), WNT4
(ANOVA, p,0.01) and RSPO1 (ANOVA, p,0.001) compared to control. Significantly higher expression of RSPO1 was detected in the ovary compared
to testis (**p,0.01). (B) Analysis of RSPO1 expression levels in the testis and ovary during this period of development. A significant increase in RSPO1
was found in the ovary across this time course (ANOVA, P,0.0001; 8w .6–7w and 9w .6–7w, both ***p,0.001) (control, 8 wpc heart).
doi:10.1371/journal.pone.0016366.g001
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mRNA expression between these two tissues (Fig. 2A). However,
the patient’s ovotestis showed reduced b-catenin protein expres-
sion as compared to a normal ovary and HEK293T cell line used
as controls, consistent with a proposed role for R-spondin1 in b-
catenin stabilization and previous findings [21] (Fig. 2B). Similar
results were seen following transfection of WT or MT RSPO1
expression vectors into HEK293T cells (data not shown). The
expression of SOX9 and WNT4 genes was also examined in vivo by
RT-PCR analysis in RNA derived from the patient’s ovotestis
(OT) and normal ovary (Ov) and testis (T) controls (Fig. 2C).
WNT4 mRNA expression levels were markedly lower in the
patient’s ovotestis compared to ovary control. SOX9 mRNA
(ENSG00000125398) expression was barely detectable both in
wild-type ovary and in ovotestis, but strongly expressed in the testis
control (Fig. 2C).
R-spondin1 augments b-catenin signaling in human cell
lines
The ability of wild-type (WT) and mutant (MT, p.Ile32_Ile95-
del) R-spondin1 to activate Wnt/b-catenin dependent targets was
investigated using the TOPFLASH (TCF) reporter system.
Transient gene expression assays of increasing concentrations of
plasmids encoding WT or MT RSPO1 showed a modest but
significant activation of the TOPFLASH reporter vector for the
WT (maximal 1.8-fold) and a complete lack of activity for the
p.Ile32_Ile95del mutant plasmid (Fig. 3A). However, this WT
activation was considerably lower than that seen when increasing
doses of a CTNNB1 (b-catenin) expression vector were studied
(maximal 7.8 fold) (Fig. 3B).
To test whether R-spondin1 could act together with b-catenin,
tsa201 cells were co-transfected with a constant concentration of a
CTNNB1 vector expressing b-catenin and with increasing
concentrations of WT or MT RSPO1 (Fig. 4A). Transfection with
2ng or 5 ng of CTNNB1/b-catenin plasmid alone activated the
TCF reporter by 2-fold and 5.3-fold, respectively (Fig. 4A, left
panel). Cells co-transfected with CTNNB1/b-catenin and WT
RSPO1 vectors showed increased activation of the reporter, up to
10-fold, indicating that R-spondin1 can augment b-catenin
activity in a dose-dependent and mildly synergistic manner
(Fig. 4A, left panel). This activation was not achieved using a
CTNNB1/b-catenin plasmid together with MT RSPO1 construct,
confirming that R-spondin1 with deletion of the furin1 domain is
inactive (Fig. 4A, right panel). Stimulation of CTNNB1/b-catenin
transfected cells with mouse recombinant R-spondin1 peptide
confirmed the ability of R-spondin1 protein to augment b-catenin
signaling (Fig. 4B).
R-spondin1 augmentation of b-catenin signaling is
partially inhibited by Dkk1
In order to investigate further the mechanism of interaction
between RSPO1 and b-catenin, cells transfected with RSPO1/R-
spondin1 and CTNNB1/b-catenin expression vectors were ex-
posed to increasing concentrations of Dickkopf-1 (DKK1)
(ENSG00000107984), a potent inhibitor of the Wnt signaling
pathway co-receptor LRP6 [17]. DKK1, at concentrations of 0–
200–400 ng/ml, showed a non-significant inhibition of RSPO1-
augmented b-catenin activation (Fig. 5A). The inhibition was not
complete even when higher concentrations of DKK1 were used in
the same assay system (data not shown). Exposure to exogenous R-
spondin1 peptide and high concentrations of DKK1 (1000 ng/ml)
resulted in a significant inhibition of TCF activation by RSPO1/
b-catenin (Fig. 5B).
R-spondin1 shows nuclear and nucleolar localization in
vitro
Plasmids encoding WT or MT RSPO1 (pRSPO1) and
expression vectors for different tagged WT and MT proteins
(pRSPO1-GFP, pRSPO1-HA) were transiently transfected into
several different cell lines (H295R, CHO, HEK293T, NT2/D1).
H295R cells expressing GFP-tagged WT RSPO1 showed that the
protein was located mostly in the nucleus and partially in the
cytoplasm (Fig. 6A). Similar results were seen in other cell lines
and using HA-tagged R-spondin1 or an anti-R-spondin1 antibody
(data not shown). All transfected cells showed this pattern of
distribution. Strong nucleolar staining was confirmed using an a-
C23 nucleolin antibody (Fig. 6B). The p.Ile32_Ile95del mutant R-
spondin1 showed a similar pattern of cellular localization (Fig. 6C).
In order to confirm this result, the subcellular localization of R-
spondin1 was also analyzed by Western blot analysis. HEK293T
cells were transfected with pRSPO1-HA WT or MT expression
vectors and fractionated protein extracts were prepared. The R-
spondin1 protein was detected in both the cytosol and nucleus, but
a definitely stronger signal was visible in the nuclear fraction
(Fig. 6D). The mutant protein also showed stronger nuclear
expression, although the overall intensity of bands was less than
WT.
Discussion
The R-spondin family of proteins are a relatively recently
identified group of furin-like domain containing factors that are
thought to play an important role in tissue development and
cellular differentiation. For example, alterations in RSPO4 activity
have been reported to cause anonychia in humans [22], whereas
disruption of Rspo2 or Rspo3 in mice affects development of
several different systems (skeletal, respiratory or placenta defects)
Figure 2. Expression analysis of factors crucial in gonadal
development following disruption of RSPO1. (A) CTNNB1 mRNA
levels, determined by RT-PCR and compared to GAPDH mRNA levels,
seem to have no difference between normal ovary (Ov) and patient’s
ovotestis (OT). (B) b-catenin protein expression appeared decreased in
ovotestis tissue compared to control ovary and HEK293T cell line, in an
immunoblot assay (as shown in Tomaselli et al, 2008 [21]). The weak
residual band may represent extracellular b-catenin, which is implicated
in cell-cell adhesion. (C) WNT4 and SOX9 mRNA levels were tested by
RT-PCR and compared to GAPDH transcript levels. WNT4 was
dramatically reduced in the patient’s ovotestis (OT) in comparison to
control ovary (Ov). SOX9 signal was detected in control testis (T), but
did not appear upregulated in the ovotestis (OT) sample compared to
the normal ovary (Ov).
doi:10.1371/journal.pone.0016366.g002
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[23]. R-spondin1 itself may protect mice from experimental colitis
or from chemotherapy or radiotherapy-induced mucosal injury
[24–26], and it is necessary for normal ductal breast development
[27]. However, it has been reports of loss-of-function mutations in
R-spondin1 in 46,XX patients with testes (‘‘testicular DSD’’) [15]
or ovotestes (‘‘ovotesticular DSD’’) [21] that have highlighted the
action of this R-spondin family member as an important mediator
of gonad development. Nevertheless, relatively little is known
about the role of R-spondin1 in early human development and the
specific mechanisms by which R-spondin1 has its effects.
Studies in the developing mouse gonad have shown that the Rspo1
gene has a sexually dimorphic expression pattern at specific
developmental stages (e12.5–e15.5), with progressively higher
expression in the ovary compared to the testis [15,23,28].
Analogous data have now been reported in other vertebrates such
as chicken, turtle and goat [28,29]. It is hypothesized that
progressive upregulation of RSPO1 expression in the developing
ovary plays an important role in opposing testis development
pathways. In the present study, we provide evidence that a similar
dimorphic pattern of RSPO1 gene expression occurs in the human
during critical early stages of testis and ovary development (between
6–9 weeks post conception), confirming the likely role of this gene as
a key component of the human gonad determination pathway.
The mechanism through which R-spondins have their effects
are not fully elucidated but it has been reported that R-spondin
proteins act primarily through upregulation of b-catenin and
canonical Wnt signaling pathways [30]. The two conserved
cysteine-rich furin-like domains of R-spondin proteins are also
thought to be important for the stabilization of cytosolic b-catenin
[18,31,32], which in turn may lead to degradation of Sox9 [33,34].
Sox9 is an autosomal gene that is upregulated in the developing
testis by steroidogenic factor-1 (SF-1) and the principle Y-
chromosomal factor, SRY [2]. However, antagonism of Sox9 in
the ovary seems necessary to prevent development of testicular
tissue, even in the absence of SRY, and now RSPO1, WNT4 and
FOXL2 are emerging as important regulators of this process
[9,14]. WNT4 may also act to prevent oocyte apoptosis in the
developing ovary [35].
Recent studies in the mouse have provided additional important
insight into the specific actions of R-spondin1. For example,
deletion of Rspo1 in XX mice results in the formation of testicular
tissue in the ovary (ovotestis) and partial androgenization of female
mice, with decreased b-catenin signaling and reduced expression of
Wnt4 [19,20]. Similarly, deletion of b-catenin in the ovary results in
down-regulation of Wnt4, but with no effect on Rspo1 expression.
Taken together, these studies suggest that b-catenin is a component
between R-spondin1 and Wnt4 [13]. The data from our patient’s
ovotestis provides direct evidence in humans to support this model,
with a reduction in b-catenin protein stability and reduced WNT4
mRNA in the gonad tissue analyzed, showing in a biological system
that these two factors are strikingly related to RSPO1. Further in vivo
data from patients with RSPO1 mutations would be needed to
confirm this finding, although to date reports of such cases are rare.
Analysis of SOX9 expression in the ovotestis from our patient did
not show any increase in SOX9 mRNA levels. This finding also
supports mouse studies described above, as Sox9 mRNA was not
increased following deletion of either Rspo1 or Ctnnb1/b-catenin in the
developing ovary [19,20,36]. These data reinforce the hypothesis that
R-spondin1 does not regulate transcription of SOX9 directly, but
influences it at the protein level. Unfortunately, it was not possible to
undertake measurements of SOX9 protein in our patient sample.
Nevertheless, it seems likely that increased SOX9 stability in the ovary
following reduction in RSPO1 or b-catenin is a central mechanism
leading to testis or ovotestis development within these tissues.
As b-catenin-mediated activation is fairly ubiquitous throughout
cellular development and function, the R-spondin family of proteins
may play an important role in mediating tissue-specific events. By
using human cell-based assay systems, we have shown that R-
Figure 3. R-spondin1 weakly activates a b-catenin-responsive promoter. (A) The effect of WT RSPO1 on TCF-dependent transcriptional
activation (left panel) was compared with that of a naturally-occurring RSPO1 mutant (MT) vector generating a protein lacking the first furin domain
(right panel), using embryonic kidney tsa201 cells and the TOPFLASH reporter construct. Transient gene expression assays of increasing
concentrations of plasmids encoding wild-type (WT) or mutant (MT) RSPO1 (0–100 ng/well) showed a mild activation (maximum 1.8-fold) of the
TOPFLASH reporter with WT RSPO1 vector (ANOVA, p,0.001) and a complete lack of activity for the mutant. (B) Dose-dependent activation of the
TOPFLASH reporter with increasing doses of beta-catenin (0–10 ng/well) (ANOVA, p,0.001). Luciferase data are reported as a mean6 SEM of at least
three triplicate experiments, standardized for Renilla co-expression (compared to basal value, **p,0.01; ***p,0.001).
doi:10.1371/journal.pone.0016366.g003
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spondin1 can act to augment b-catenin signaling in a dose-dependent
manner. This effect could have a significant biological effect at times
when relative dosage effects of sex-determining genes and proteins are
important. It is emerging that gene dosage effects are crucial during
early gonad development in humans and other species. Furthermore,
we have provided the first evidence in humans to shown that
expression levels of CTNNB1 andWNT4 mRNA are similar in testes
and ovaries during these critical stages of early ovary development.
Thus, R-spondin1 may act as a tissue (ovary) and time specific
amplifier of b-catenin activity. By our functional experiments we have
also shown that the mutant RSPO1 protein in our patient was not
able to activate the TCF promoter, confirming in vitro an essential role
of the furin domain for RSPO1 activity or stability.
R-spondin proteins may also interact with members of the Wnt
pathway in a synergistic manner. For example, it has been
reported that human Rspo1 synergizes with Wnt3a to stabilize b-
catenin and that this synergy occurs in the extracellular
environment [18,32,37]. Generally, R-spondins are believed to
be secreted proteins that can modulate Wnt signaling by
antagonizing internalization of the Wnt co-receptor, LRP6 [16].
Mechanistically R-spondin1 may compete with Dickkopf-1
(DKK1) for binding to Kremen, which allows LRP6 to become
available to upregulate Wnt signaling [17]. To investigate whether
the synergistic effect between RSPO1 and b-catenin could be
related to R-spondin1-regulated levels of LRP6 on the cell surface,
we treated RSPO1/b-catenin transfected cells with different doses
of DKK1, a potent inhibitor of LRP6. DKK1 reduced the
augmented b-catenin activity induced by RSPO1/R-spondin1,
consistent with a significant interaction with LRP6, but did not
abolish it completely. These data differ from the complete loss of
reporter activity with DKK1 in studies of Wnt3a/RSPO1 synergy
[18], and suggest that residual TCF activity could be related to an
additional and alternative mechanism of RSPO1 action that is
unrelated to inhibition of Kremen/DKK1-dependent LRP6
internalization. R-spondin1 has been shown to contain a
carboxyl-terminal putative nuclear localization signal [16,38]
and we have used several different experimental approaches to
show strong nuclear and nucleolar localization of R-spondin1 in
Figure 4. R-spondin1 augments b-catenin signaling. (A) Co-transfection of increasing doses of wild-type (WT) RSPO1 (0–100 ng/well) with b-
catenin (0–5 ng/well) showed dose-dependent augmentation of b-catenin signaling (left panel) (ANOVA: CTNNB1 0 ng, p,0.05; CTNNB1 2 ng,
p,0.01; CTNNB1 5 ng, p = 0.07). A statistically significant synergistic effect was seen when doses of 10 ng RSPO1 and 50 ng RSPO1 were transfected
on the background of increasing doses of CTNNB1 (ANOVA: RSPO1 10 ng, p,0.05; RSPO1 50 ng, p,0.05). No activity was seen after co-transfection
of mutant (MT) RSPO1 (0–100 ng/well) (right panel). (B) Relative luciferase activity after stimulation of b-catenin transfected cells with Rspo1 peptide
(0–3000 ng/ml) (ANOVA: CTNNB1 -, p,0.01; CTNNB1 +, p,0.001). Luciferase data are reported as a mean 6 SEM of at least three triplicate
experiments, standardized for Renilla co-expression (*p,0.05; **p,0.01; ***p,0.001 compared to basal value without RSPO1 vector or peptide for
that study).
doi:10.1371/journal.pone.0016366.g004
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several different cell-based systems. Whether these direct nuclear
effects of R-spondin1 are important at key stages of gonad
development is not known, although this could represent an
additional mechanism for the effect of this protein in regulating
ovary development and in preventing activation of testis-specific
pathways. Of note, the p.Ile32_Ile95del mutant R-spondin1
showed a reduced expression level compared to the wild-type
protein, by both western blotting and immunofluorescence
analysis. This lower expression could be due to reduced stability
of the mutant protein lacking the furin domain, and could have
contributed in part to its impaired activation of the TCF promoter.
Taken together, these findings confirm that R-spondin1 is a key
regulator of ovary development in humans and that this factor
may represent a tissue- and time-specific modulator of b-catenin
signaling. Our results support the model that ovary-specific genes,
such as RSPO1, are actively upregulated at critical stages of
development to oppose pathways that would otherwise lead to
testis development, by several different mechanisms of action.
Materials and Methods
Ethics statement
Anonymized human embryonic/fetal material was obtained
from the Medical Research Council-Wellcome Trust Human
Developmental Biology Resource with written consent and ethical
approval from the local Research Ethics Committee of University
Figure 5. Effect of DKK1 treatment on R-spondin1 augmentation of b-catenin signaling. (A) RSPO1/b-catenin co-transfected cells were
treated 2 hours before transfection with different doses of DKK1 (0–400 ng/ml). After 24 h, cells were lysed and assayed for luciferase activity. No
significant reduction in stimulation was seen (ANOVA: RSPO1 50 ng, p = 0.15). (B) Cells were treated with DKK1 (0–1000 ng/ml) and stimulated with
Rspo1 peptide (0–2000 ng/ml). Luciferase activity was measured 24 h later. Luciferase data are reported as a mean 6 SEM of at least three triplicate
experiments, standardized for Renilla co-expression. (N.S., not significant; *p,0.05).
doi:10.1371/journal.pone.0016366.g005
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College London Hospitals and the Royal Free Hospital Research
Ethics Committee (08/H0712/34). We obtained tissue samples for
genetic and molecular studies after receiving informed consent
from the patient, following approval from the Research Ethics
Committee of the San Camillo-Forlanini Hospital.
Fetal gonad RNA preparation
Human testes and ovaries (n = 3 each) from Carnegie stage (CS)
18–21 (6–7 weeks post conception, wpc), Fetal stage 1 (F1) (8wpc)
and F2 (9wpc) were obtained on ice and preserved in RNA later
(Ambion). Fetal heart tissue (8wpc) was used as a control. RNA
was extracted using the Trizol method and the concentration and
ratio of absorbance at 260 nm to 280 nm (A260/A280 ratio) were
measured using a NanoDrop ND-1000 Spectrophotometer
(NanoDrop Technologies, Witec, Littau, Switzerland). First-strand
cDNA was synthesized using the SuperScript II Reverse
Transcriptase (Invitrogen) and random primers according to the
manufacturer’s instructions. The amount of input RNA in each
reaction was calculated to be 200 ng.
qRTPCR of CTNNB1, WNT4 and RSPO1
Primers and TaqManH probes were obtained for CTNNB1,
WNT4, and RSPO1 (Applied Biosystems). Amplification was
performed in a total volume of 20 ml per reaction using TaqManH
Gene Expression Master Mix and a StepOne Real-Time PCR
system (Applied Biosystems). Thermocycling conditions consisted
of an initial step of 2 min at 50uC, denaturation of 10 min at
95uC, followed by 40 cycles of 95uC for 15 s and 60uC for 1 min.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used
for normalization and relative quantification of gene expression
Figure 6. R-spondin1 can show nuclear and nucleolar localization. (A) Immunofluorescent microscopy was used to detect the cellular
distribution of a WT pRSPO1-GFP vector in H295R cells (left panel). DAPI stained nuclei and merged images are shown (center and right panels,
respectively) (magnification 20X). (B) A similar pattern of cellular distribution was obtained in a CHO cell line (left panel). Fluorescent labeling
performed with an antibody against C23-nucleolar protein (red) revealed that the GFP-tagged WT RSPO1 protein shows strong nucleolar localization
in some of these cells (center and right panels) (magnification 20X). (C) Immunofluorescent analysis of MT pRSPO1-GFP showed similar cellular
distribution. (D) The strong nuclear localization was confirmed following Western blot analysis of nuclear and cytosolic extracts prepared from
HEK293T cells that had been transfected with either WT or MT pRSPO1-HA constructs.
doi:10.1371/journal.pone.0016366.g006
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was performed according to the 2-DDCt method [39]. Results are
expressed as fold change above control.
RT-PCR of ovotestis
Total RNA was isolated from patient’s gonadal tissue and from
normal human ovary and testis using the Chomczynski and Sacchi
extraction protocol [40]. RT-PCR was performed (GeneAmp
RNA PCR Kit, Applied Biosystems) and CTNNB1 (encoding b-
catenin), SOX9 and WNT4 were amplified using gene-specific
primers (sequences and conditions available on request). RT-PCR
of GAPDH was used as a positive control.
Western blots
Western blots to assess total b-catenin expression were
performed using total proteins extracted from patient’s gonadal
tissue and normal human ovary as described previously, using a
mouse monoclonal anti-b-catenin antibody (Santa Cruz Biotech-
nology, Santa Cruz, CA) [21].
DNA constructs
A DNA fragment encoding full-length wild-type (WT) R-spondin1
was amplified from normal ovary tissue. A corresponding DNA
fragment encoding mutant (MT, p.Ile32_Ile95del) human R-
spondin1 was amplified from the ovotestis of a patient with
ovotesticular DSD [21]. The amplified regions were verified by
sequencing and cloned into a pcDNA3.1(+) plasmid (Invitrogen) for
expression in mammalian cells (pRSPO1 WT and MT). These
cDNAs were also cloned into a pEGFP-N1 vector (Clontech) to
producemutant fusion proteins with a green fluorescent protein (GFP)
tag at the carboxyl-terminus of RSPO1 (pRSPO1-GFP WT and
MT), as well as into a pcDNA3.1(+) vector to generate wild-type or
mutant RSPO1 with an in-frame fusion to a carboxyl-terminal
hemagglutinin (HA) epitope tag (pRSPO1-HA WT and MT). The
expression vector encoding wild-type b-catenin was generated from
full-length human CTNNB1 (IMAGEConsortiumCloneID 6151332).
Cell culture
Human embryonic kidney 293T (HEK293T) cells (American
Type Culture Collection, ATCC), human embryonic kidney tsa201
cells [41], NT2/D1 human embryonal testicular carcinoma cells
(ATCC), and chinese hamster ovary (CHO) cells (ATCC) were
routinely maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum (FBS),
100 U/ml penicillin and 100 mg/ml streptomycin in 5% CO2 at
37uC (10% CO2 for NT2/D1). NCI-H295R human adrenal
carcinoma cells (ATCC) were grown in DMEM/F12 1:1 containing
2.5% Nu-Serum and ITS+ Premix (1X) (BD Biosciences).
Transient gene expression assays
Transient gene expression assays were performed using
Lipofectamine2000 (Invitrogen) and a Dual-Luciferase Reporter
Assay System (Promega) in accordance with the manufacturer’s
instructions. Cells (tsa201) were seeded in 96-well plates (TPP)
24 h prior to transfection. Varying amounts (0–100 ng/well) of
either WT or MT pRSPO1 plasmids were transfected with or
without varying amounts (0–5 ng/well) of b-catenin vector. The
TOPFLASH reporter plasmid (100 ng/well), containing TCF-
binding sites linked to luciferase, was used to assess target gene
activation [42]. Co-transfection of pRLSV40 Renilla luciferase
(Promega) was used as an internal control of transfection
efficiency. Luciferase assays were performed 24 hours after
transfection using a FLUOstar Optima fluorescence microplate
reader (BMG Labtech) and luciferase activity was normalized to
Renilla co-expression. Results are shown as the mean 6 SEM for
triplicate samples of at least three independent experiments.
Recombinant R-spondin1
Recombinant mouse R-spondin1 (0–3000 ng/ml final concen-
tration) (R&D Systems) was added to culture media 24 hours prior
to luciferase assay and 48 hours prior to immunocytochemistry
studies.
LRP6 inhibition
Human recombinant DKK1 protein (0–1000 ng/ml final
concentration) (R&D Systems) was used to block LRP6 activity.
This peptide was added to cultured media 2 hours prior to
transfection or stimulation.
Cellular immunohistochemistry
Empty vector, WT and MT pRSPO1, p-RSPO1-GFP, or
pRSPO1-HA expression vectors (0.8 mg/chamber) were transfect-
ed into several different cell lines (HEK293T, tsa201, NT2/D1,
CHO and H295R) seeded in 8-chamber slides using Lipofecta-
mine2000 (Invitrogen). After 24–48 hours, cells were fixed and
permeabilized with TritonX-100 (0.3%) prior to immunohisto-
chemistry using standard protocols. The following primary
antibodies were used: rabbit polyclonal anti-HA (1:25) (Sigma),
human/mouse monoclonal anti-RSPO1 (1:150-1:200) (R&D
Systems) and rabbit polyclonal a-C23 anti-nucleolin (1:100) (Santa
Cruz Biotechnology). Nuclear counter staining was performed
with Vectashield containing DAPI (Vector Laboratories). Cells
were visualized on a Zeiss Axioskop microscope and images
captured using a ZeissAxiocam camera.
Subcellular localization by Western blot analysis
HEK293T cells were transiently transfected with either WT or
MT pRSPO1-HA expression vectors (0.8 mg/well) using Lipofecta-
mine 2000 (Invitrogen). After 48–72 hours, cytoplasmic and nuclear
protein extracts were prepared using a modified version of the
Dignam protocol [43]. Protein concentrations were measured by the
BCA assay (Bio-Rad Laboratories). Fifty micrograms of protein
extract from each sample was subjected to SDS/PAGE, transferred
to polyvinylidene fluoride (PVDF) membranes (Millipore) and probed
with the following antibodies: anti-HA probe (1:500) (sc-7392, Santa
Cruz Biotechnology Inc.) or anti-R-spondin1 (1:300) (AF3474, R&D
Systems). Bound antibodies were detected with enhanced chemilu-
minescence (ECL kit, Amersham). Apparent molecular weight values
were estimated using the ColorBurst Electrophoresis Marker (Sigma).
b-actin (clone AC-15, Sigma) hybridization was performed as a
control for protein loading.
Statistical analysis
All values are expressed as mean 6 SEM unless indicated
otherwise. Comparison of means between multiple groups was
performed using one-way analysis of variance (ANOVA) with
Bonferroni corrections for multiple comparisons where significant
differences were found. Comparison of means between two groups
was undertaken using unpaired two-tailed Student’s t-tests. P
values were calculated using GraphPad and the statistical analysis
function in Microsoft ExcelH (2007 version). Significance is
expressed at *p#0.05; **p#0.01; ***p#0.001.
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